I.P. Pavlov Journal of Higher Nervous ActivityI.P. Pavlov Journal of Higher Nervous ActivityЖурнал высшей нервной деятельности им. И.П. Павлова0044-46773034-5316The Russian Academy of Sciences65208610.31857/S0044467724030011ОБЗОРЫ И ТЕОРЕТИЧЕСКИЕ СТАТЬИResearch ArticleRole of individual structural and functional elements of myelin in Parkinson’s diseaseГены белков миелина, экспрессия которых связана с болезнью ПаркинсонаShulskayaM. V.ШульскаяМ. В.
Russian Federation
shulskaya.m@yandex.ruSlominskyP. A.СломинскийП. А.
Russian Federation
shulskaya.m@yandex.ruShadrinaM. I.ШадринаМ. И.
Russian Federation
shulskaya.m@yandex.ruAlievaA. K.АлиеваА. Х.
Russian Federation
shulskaya.m@yandex.ruNational Research Center “Kurchatov Institute”Национальный исследовательский центр “Курчатовский институт”2410202474325926802022025Copyright ©; 2024, Russian Academy of SciencesCopyright ©; 2024, Российская академия наук2024Russian Academy of SciencesРоссийская академия наукhttps://innoscience.ru/0044-4677/article/view/652086

Myelin is a highly specialized form of the plasma membrane. The gradual loss of myelin is typical for both age-related and pathological changes in the brain. In this review, we attempted to characterize the spectrum of genes which products are involved in the formation and functioning of CNS myelin, as well as to assess their possible contribution to the pathogenesis of PD. Analysis of currently published data obtained from model objects and patients with PD has identified several myelin protein genes that may be associated with the development of PD. The PLP1, MOBP, FA2H, and HSPA8 genes are the most promising for studying their contribution to the pathogenesis of PD.

Миелин представляет собой высокоспециализированную форму плазматической мембраны. Постепенная потеря миелина является одним из характерных признаков как возрастных, так и патологических изменений мозга. В данном обзоре мы попытались охарактеризовать спектр генов, чьи продукты принимают участие в формировании и функционировании миелина ЦНС, а также оценить их возможный вклад в патогенез БП. Анализ опубликованных в настоящее время данных, полученных на модельных объектах и пациентах с БП, позволил выявить несколько генов белков миелина, которые могут быть связаны с развитием БП. Гены PLP1, MOBP, FA2H и HSPA8 являются наиболее перспективными для исследования их вклада в патогенез БП.

myelinaxonmyelinationParkinson’s diseaseмиелинаксонмиелинизацияболезнь ПаркинсонаРоссийский научный фондRussian Science Foundation20-15-00262The work of Marina Shulskaya and Petr Slominsky was carried out within the framework of the state assignment of the National Research Center “Kurchatov Institute” (GZ - 5F - IMG.9). The work of Maria Shadrina and Aneli Aliyeva was carried out with partial financial support from the Russian Science Foundation (RSF) (agreement No. 20-15-00262).Работа Марины Шульской, Петра Сломинского проведена в рамках выполнения государственного задания НИЦ “Курчатовский институт” (ГЗ - 5Ф - ИМГ.9). Работа Марии Шадриной, Анели Алиевой проведена при частичной финансовой поддержке Российским научным фондом (РНФ) (соглашение № 20-15-00262).Airola M.V., Hannun Y.A. Sphingolipid metabolism and neutral sphingomyelinases. Handb. Exp. Pharmacol. 2013. 215: 57–76.Alieva A.K., Zyrin V.S., Rudenok M.M., Kolacheva A.A., Shulskaya M.V., Ugryumov M.V. et al. Whole-transcriptome analysis of mouse models with MPTP-induced early stages of Parkinson’s disease reveals stage-specific response of transcriptome and a possible role of myelin-linked genes in neurodegeneration. Mol. Neurobiol. 2018. 55 (9): 7229–7241.Almeida R.G., Williamson J.M., Madden M.E., Early J.J., Voas M.G., Talbot W.S. et al. Myelination induces axonal hotspots of synaptic vesicle fusion that promote sheath growth. Curr. Biol. 2021. 31 (17): 3743–3754.Altevogt B.M., Kleopa K.A., Postma F.R., Scherer S.S., Paul D.L. Connexin29 is uniquely distributed within myelinating glial cells of the central and peripheral nervous systems. J. Neurosci. 2002. 22 (15): 6458–6470.Bakhti M., Winter C., Simons M. Inhibition of myelin membrane sheath formation by oligodendrocyte-derived exosome-like vesicles. J. Biol. Chem. 2011. 286 (1): 787–796.Bandres-Ciga S., Cookson M.R., Saez-Atienzar S., Bonet-Ponce L., Billingsley K., Vitale D., Blauwendraat C., Gibbs J.R. et al. International Parkinson›s Disease Genomics Consortium (IPDGC).Baron W., Hoekstra D.On the biogenesis of myelin membranes: sorting, trafficking and cell polarity. 2010. FEBS Lett. 584 (9): 1760–1770.Beilina A. Genes associated with Parkinson’s disease: regulation of autophagy and beyond. J Neurochem. 2016. 139, Suppl 1: 91–107.Benger M., Mankad K., Proukakis C., Mazarakis N.D., Kinali M. The Interaction of Genetic Mutations in PARK2 and FA2H Causes a Novel Phenotype in a Case of Childhood-Onset Movement Disorder. 2019. Front. Neurol. 10: 555.Bernardo A., De .Nuccio C., Visentin S., Martire A., Minghetti L., Popoli P., Ferrante A. Myelin Defects in Niemann-Pick Type C Disease: Mechanisms and Possible Therapeutic Perspectives. Int. J. Mol. Sci. 2021. 22 (16).Bernheimer H., Birkmayer W., Hornykiewicz O., Jellinger K., Seitelberger F. Brain dopamine and the syndromes of Parkinson and Huntington. Clinical, morphological and neurochemical correlations. J Neurol Sci. 1973. 20: 415–455.Birling M.C., Tait S., Hardy R.J., Brophy J. A novel rat tetraspan protein in cells of the oligodendrocyte lineage. J. Neurochem. 1999. 73 (6): 2600–2608.Blokhin V., Shupik M., Gutner U., Pavlova E., Lebedev A.T., Maloshitskaya O. et al. The Sphingolipid Asset Is Altered in the Nigrostriatal System of Mice Models of Parkinson’s Disease. Biomolecules. 2022. 12 (1): 93.Bonam S.R., Ruff M., Muller S. HSPA8/HSC70 in Immune Disorders: A Molecular Rheostat that Adjusts Chaperone-Mediated Autophagy Substrates. Cells. 2019. 8 (8).Bose A., Beal M.F. Mitochondrial dysfunction in Parkinson’s disease. J Neurochem. 2016. 139 Suppl 1: 216–231.Bouscary A., Quessada C., Rene F., Spedding M., Turner B.J., Henriques A. et al. Sphingolipids metabolism alteration in the central nervous system: Amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases. Semin Cell. Dev. Biol. 2021. 112: 82–91.Braak H., Del Tredici K. Poor and protracted myelination as a contributory factor to neurodegenerative disorders. Neurobiol. Aging. 2004. 25 (1): 19–23.Braak H., Del Tredici K. Neuroanatomy and pathology of sporadic Parkinson’s disease. Adv. Anat. Embryol. Cell Biol. 2009. 201: 1–119.Cataldi S., Arcuri C., Hunot S., Légeron F.-P., Mecca C., Garcia-Gil M. et al. Neutral Sphingomyelinase Behaviour in Hippocampus Neuroinflammation of MPTP-Induced Mouse Model of Parkinson’s Disease and in Embryonic Hippocampal Cells. Mediators of Inflammation. 2017. 2017: 2470950.Cermenati G., Mitro N., Audano M., Melcangi R.C., Crestani M., De Fabiani E., Caruso D. Lipids in the nervous system: from biochemistry and molecular biology to patho-physiology. Biochim. Biophys. Acta. 2015. 1851 (1): 51–60.Chatterjee M., van Steenoven I., Huisman E., Oosterveld L., Berendse H., van der Flier W.M. et al. Contactin-1 Is Reduced in Cerebrospinal Fluid of Parkinson’s Disease Patients and Is Present within Lewy Bodies. Biomolecules. 2020. 10 (8).Clements C.S., Reid H.H., Beddoe T., Tynan F.E., Perugini M.A., Johns T.G. et al. The crystal structure of myelin oligodendrocyte glycoprotein, a key autoantigen in multiple sclerosis. Proc. Natl. Acad. Sci. USA. 2003. 100 (19): 11059–11064.Çolakoğlu G., Bergstrom-Tyrberg U., Berglund E.O., Ranscht B. Contactin-1 regulates myelination and nodal/paranodal domain organization in the central nervous system. Proc. Natl. Acad. Sci. USA. 2014. 111 (3): E394–403.Cookson M.R., Hardy J., Lewis P.A. Genetic neuropathology of Parkinson’s disease. Int. J. Clin. Exp. Pathol. 2008. 1: 217–231.Custodia A., Aramburu-Núñez M., Correa-Paz C., Posado-Fernández A., Gómez-Larrauri A., Castillo J. et al. Ceramide Metabolism and Parkinson’s Disease-Therapeutic Targets. Biomolecules. 2021. 11 (7).Dagan E., Adir V., Schlesinger I., Borochowitz Z., Ayoub M., Mory A. et al. SMPD1 mutations and Parkinson disease. Parkinsonism Relat. Disord. 2015. 21 (10): 1296–1297.Dean D.C.3rd, Hurley S.A., Kecskemeti S.R., O’Grady J.P., Canda C., Davenport-Sis N.J. et al. Association of Amyloid Pathology With Myelin Alteration in Preclinical Alzheimer Disease. JAMA Neurol. 2017. 74 (1): 41–49.Ding W.X., Yin X.M. Mitophagy: mechanisms, pathophysiological roles, and analysis. Biol Chem. 2012. 393 (7): 547–564.Domingues H.S., Portugal C.C., Socodato R., Relvas J.B. Oligodendrocyte, Astrocyte, and Microglia Crosstalk in Myelin Development, Damage, and Repair. Front. Cell Dev. Biol. 2016. 4.Dong-Chen X., Yong C., Yang X., Chen-Yu .S., Li-Hua P. Signaling pathways in Parkinson’s disease: molecular mechanisms and therapeutic interventions. Signal Transduction and Targeted Therapy. 2023. 8 (1): 73.Dutta D.J., Woo D.H., Lee P.R., Pajevic S., Bukalo O., Huffman W.C. et al. Regulation of myelin structure and conduction velocity by perinodal astrocytes. Proc. Natl. Acad. Sci. USA. 2018. 115 (46): 11832–11837.Ebanks K., Lewis P.A., Bandopadhyay R. Vesicular Dysfunction and the Pathogenesis of Parkinson’s Disease: Clues From Genetic Studies. Front. Neurosci. 2019. 13: 1381.Etxeberria A., Hokanson K.C., Dao D.Q., Mayoral S.R., Mei F., Redmond S.A., et al. Dynamic Modulation of Myelination in Response to Visual Stimuli Alters Optic Nerve Conduction Velocity. J. Neurosci. 2016. 36 (26): 6937–6948.Ford M.C., Alexandrova O., Cossell L., Stange-Marten A., Sinclair J., Kopp-Scheinpflug C. et al. Tuning of Ranvier node and internode properties in myelinated axons to adjust action potential timing. Nat. Commun. 2015. 6: 8073.Fowler C.J. Update on the neurology of Parkinson’s disease. Neurourol Urodyn. 2007. 26 (1): 103–109.Frid K., Einstein O., Friedman-Levi Y., Binyamin O., Ben-Hur T., Gabizon R. Aggregation of MBP in chronic demyelination. Ann. Clin. Transl. Neurol. 2015. 2 (7): 711–721.Gan-Or .Z., Orr-Urtreger A., Alcalay R.N., Bressman S., Giladi N., Rouleau G.A. The emerging role of SMPD1 mutations in Parkinson’s disease: Implications for future studies. Parkinsonism Relat. Disord. 2015. 21 (10): 1294–1295.Garcia-Gil M., Albi E. Nuclear Lipids in the Nervous System: What they do in Health and Disease. Neurochem. Res. 2017. 42 (2): 321–336.Gargareta V.I., Reuschenbach J., Siems S.B., Sun T., Piepkorn L., Mangana C. et al. H.B. Conservation and divergence of myelin proteome and oligodendrocyte transcriptome profiles between humans and mice. Elife. 2022. 11.Greer J.M., Lees M.B. Myelin proteolipid protein – the first 50 years. Int. J. Biochem. Cell Biol. 2002. 34 (3): 211–215.Harauz G., Ladizhansky V., Boggs J.M. Structural polymorphism and multifunctionality of myelin basic protein. Biochem. 2009. 48 (34): 8094–8104.Harayama T., Riezman H. Understanding the diversity of membrane lipid composition. Nat. Rev. Mol. Cell Biol. 2018. 19 (5): 281–296.Hauser M.A., Li .Y.J., Xu .H., Noureddine M.A., Shao Y.S., Gullans S.R. et al. Expression profiling of substantia nigra in Parkinson disease, progressive supranuclear palsy, and frontotemporal dementia with parkinsonism. Arch. Neurol. 2005. 62 (6): 917–921.Hentrich T., Wassouf Z., Ehrhardt C., Haas E., Mills J.D., Aronica E. et al. Increased expression of myelin-associated genes in frontal cortex of SNCA overexpressing rats and Parkinson’s disease patients. Aging (Albany NY). 2020. 12 (19): 18889–18906.Hines J.H., Ravanelli A.M., Schwindt R., Scott E.K., Appel B. Neuronal activity biases axon selection for myelination in vivo. Nat. Neurosci. 2015. 18 (5): 683–689.Hofmann K., Tomiuk S., Wolff G., Stoffel W. Cloning and characterization of the mammalian brain-specific, Mg2+-dependent neutral sphingomyelinase. Proc. Natl. Acad. Sci. USA. 2000. 97 (11): 5895–5900.Imai Y., Soda M., Inoue H., Hattori N., Mizuno Y., Takahashi R. An unfolded putative transmembrane polypeptide, which can lead to endoplasmic reticulum stress, is a substrate of Parkin. Cell. 2001. 105 (7): 891–902.Jacak J.E., Jacak W.A. The Role of Myelin in Malfunctions of Neuron Transmittance. Neurosci. 2022. 505: 125–156.Jayakrishna T., Nellore J., Veerappan V. Gender specific mRNA expression of HSPA8 in Parkinson’s disease. 2020. 3391–3395.Jin T., Gu .J., Li .Z., Xu .Z., Gui Y. Recent Advances on Extracellular Vesicles in Central Nervous System Diseases. Clin. Interv. Aging. 2021. 16: 257–274.Kohama S.G., Rosene D.L., Sherman L.S. Age-related changes in human and non-human primate white matter: from myelination disturbances to cognitive decline. Age (Dordr). 2012. 34 (5): 1093–1110.Kon T., Tanji K., Mori F., Kimura A., Kakita A., Wakabayashi K. Immunoreactivity of myelin-associated oligodendrocytic basic protein in Lewy bodies. Neuropat. 2019. 39 (4): 279–285.Koudelka S., Voas M.G., Almeida R.G., Baraban M., Soetaert J., Meyer M.P. et al. Individual Neuronal Subtypes Exhibit Diversity in CNS Myelination Mediated by Synaptic Vesicle Release. Curr. Biol. 2016. 26 (11): 1447–1455.Kramer-Albers E.M., Bretz N., Tenzer S., Winterstein C., Mobius W., Berger H. et al. Oligodendrocytes secrete exosomes containing major myelin and stress-protective proteins: Trophic support for axons? Proteomics Clin. Appl. 2007. 1 (11): 1446–1461.Kruer M.C., Paisan-Ruiz C., Boddaert N., Yoon M.Y., Hama H., Gregory A. et al. Defective FA2H leads to a novel form of neurodegeneration with brain iron accumulation (NBIA). Ann. Neurol. 2010. 68 (5): 611–618.Kurkowska-Jastrzebska I., Bałkowiec-Iskra E., Ciesielska A., Joniec I., Cudna A., Zaremba M.M. et al. Decreased inflammation and augmented expression of trophic factors correlate with MOG-induced neuroprotection of the injured nigrostriatal system in the murine MPTP model of Parkinson’s disease. Int. Immunopharmacol. 2009. 9 (6): 781–791.Lin M.K., Farrer M.J. Genetics and genomics of Parkinson’s disease. Genome Med. 2014. 6 (6): 48.Lopez P.H. Role of myelin-associated glycoprotein (siglec-4a) in the nervous system. Adv. Neurobiol. 2014. 9: 245–262.Mao C.Y., Yang J., Wang H., Zhang S.Y., Yang Z.H. et al. SMPD1 variants in Chinese Han patients with sporadic Parkinson’s disease. Parkinsonism Relat. Disord. 2017. 34: 59–61.Montague P., McCallion A.S., Davies R.W., Griffiths I.R. Myelin-associated oligodendrocytic basic protein: a family of abundant CNS myelin proteins in search of a function. Dev. Neurosci. 2006. 28 (6): 479–487.Nave K.A. Myelination and support of axonal integrity by glia. Nature. 2010. 468 (7321): 244–252.Olsen A.S.B., Faergeman N.J. Sphingolipids: membrane microdomains in brain development, function and neurological diseases. Open Biol. 2017. 7 (5).Papagiannakis N., Xilouri M., Koros C., Stamelou M., Antonelou R., Maniati M. et al. Lysosomal alterations in peripheral blood mononuclear cells of Parkinson’s disease patients. Mov. Disord. 2015. 30 (13): 1830–1834.Papuc E., Rejdak K. The role of myelin damage in Alzheimer’s disease pathology. Arch. Med. Sci. 2020. 16 (2): 345–351.Pierre Morell R.H.Q. Characteristic Composition of Myelin. Basic Neurochemistry: Molecular, Cellular and Medical Aspects. 6th edition, Siegel, GJ, Albers, RW, et al., Eds., Philadelphia: Lippincott-Raven, 1999.Quarles R.H. Myelin-associated glycoprotein (MAG): past, present and beyond. J. Neurochem. 2007. 100 (6): 1431–1448.Redeker V., Pemberton S., Bienvenut W., Bousset L., Melki R. Identification of protein interfaces between alpha-synuclein, the principal component of Lewy bodies in Parkinson disease, and the molecular chaperones human Hsc70 and the yeast Ssa1p. J. Biol. Chem. 2012. 287 (39): 32630–32639.Saab A.S., Nave K.A. Myelin dynamics: protecting and shaping neuronal functions. Curr. Opin. Neurobiol. 2017. 47: 104–112.Schneider S., Gruart A., Grade S., Zhang Y., Kroger S., Kirchhoff F. at al. Decrease in newly generated oligodendrocytes leads to motor dysfunctions and changed myelin structures that can be rescued by transplanted cells. Glia. 2016. 64 (12): 2201–2218.Schuchman E.H., Wasserstein M.P. Types A and B Niemann-Pick disease. Best Pract. Res. Clin. Endocrinol. Metab. 2015. 29 (2): 237–247.Shimura H., Schlossmacher M.G., Hattori N., Frosch M.P., Trockenbacher A., Schneider R. et al. Ubiquitination of a new form of alpha-synuclein by parkin from human brain: implications for Parkinson’s disease. Science. 2001. 293 (5528): 263–269.Signorelli P., Conte C., Albi E. The Multiple Roles of Sphingomyelin in Parkinson’s Disease. Biomolecules. 2021. 11 (9).Simons M., Nave K.A. Oligodendrocytes: Myelination and Axonal Support. Cold Spring Harb. Perspect. Biol. 2015. 8 (1): a020479.Siokas V., Aloizou A.-M., Liampas I., Bakirtzis C., Tsouris Z., Sgantzos M. et al. Myelin-associated oligodendrocyte basic protein rs616147 polymorphism as a risk factor for Parkinson’s disease. Acta Neurol. Scand. 2022. 145 (2): 223–228.Smith B.M., Giddens M.M., Neil J., Owino S., Nguyen T.T., Duong D. et al. Mice lacking Gpr37 exhibit decreased expression of the myelin-associated glycoprotein MAG and increased susceptibility to demyelination. Neurosci. 2017. 358: 49–57.Vacic V., Ozelius L.J., Clark L.N., Bar-Shira A., Gana-Weisz M., Gurevich T. et al. Genome-wide mapping of IBD segments in an Ashkenazi PD cohort identifies associated haplotypes. Hum. Mol. Genet. 2014. 23 (17): 4693–4702.Voigt A., Berlemann L.A., Winklhofer K.F. The mitochondrial kinase PINK1: functions beyond mitophagy. J Neurochem. 2016. 139 Suppl 1: 232–239.Vos M., Klein C., Hicks A.A. Role of Ceramides and Sphingolipids in Parkinson’s Disease. J. Mol. Biol. 2023. 435 (12): 168000.Yamamoto Y., Mizuno R., Nishimura T., Ogawa Y., Yoshikawa H., Fujimura H. et al. Cloning and expression of myelin-associated oligodendrocytic basic protein. A novel basic protein constituting the central nervous system myelin. J. Biol. Chem. 1994. 269 (50): 31725–31730.Yang H.-J., Vainshtein A., Maik-Rachline G., Peles E. G protein-coupled receptor 37 is a negative regulator of oligodendrocyte differentiation and myelination. Nat. Commun. 2016. 7 (1): 10884.Yaseen I.H., Monk P.N., Partridge L.J. Tspan2: a tetraspanin protein involved in oligodendrogenesis and cancer metastasis. Biochem. Soc. Trans. 2017. 45 (2): 465–475.Ye. H., Robak L.A., Yu. M., Cykowski M., Shulman J.M. Genetics and Pathogenesis of Parkinson’s Syndrome. Annu Rev Pathol 2023. 18: 95–121.Youle R.J., Narendra D.P. Mechanisms of mitophagy. Nat Rev Mol Cell Biol 2011. 12 (1): 9–14.Zalc B. The acquisition of myelin: a success story. Novartis Found Symp. 2006. 276: 15–21.